Drugs / Bradanicline
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01254448 | Sep 2010 → Mar 2011 | Alzheimer disease | Targacept Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03622216 | Nov 2018 → May 2019 | respiratory system disorder | Attenua, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01488929 | Dec 2011 → Nov 2013 | schizophrenia | Targacept Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01003379 | Oct 2009 → Nov 2010 | schizophrenia | Targacept Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01124708 Comparator | May 2010 → Feb 2011 | attention deficit-hyperactivity disorder | Targacept Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bradanicline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03622216 ↗ |
| Known as | ATA-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1258006 ↗ |
| Known as | Bradaniclina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1258006 ↗ |
| Known as | BRADANICLINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1258006 ↗ |
| Known as | TC-5619 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01003379 ↗ |
| Known as | TC-5619-023 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1258006 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL1258006 ↗ |
| Modality | Small molecule | — CHEMBL1258006 ↗ |
| Route | Oral | “one capsule once daily p.o.” NCT01124708 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL1258006 ↗ |